PITTSBURGH--A study has begun to determine the effectiveness of
tamoxifen (Nolvadex) in preventing osteoporosis in a group of
women participating in the Breast Cancer Prevention Trial (BCPT),
coordinated by the National Surgical Adjuvant Breast and Bowel
The Bone Mineral Density and Biochemical Marker Study (BMDS) will
involve 384 women (half premenopausal and half postmenopausal)
randomized to receive tamoxifen or placebo.
The trial will study the effects of tamoxifen on both bone density
and biochemical markers of bone turnover over a period of at least
5 years. Data on bone fractures also will be collected on the
entire BCPT population of 16,000 women for at least 5 years.
"Most previous studies using tamoxifen have been in animals
or in post-menopausal women with breast cancer, a disease that
itself may affect bone loss," said Normal Wolmark, MD, of
the NSABP Operations Office.